PE20141649A1 - Composiciones farmaceuticas que comprenden 40-o-(2-hidroxi)etil-rapamicina - Google Patents
Composiciones farmaceuticas que comprenden 40-o-(2-hidroxi)etil-rapamicinaInfo
- Publication number
- PE20141649A1 PE20141649A1 PE2014000448A PE2014000448A PE20141649A1 PE 20141649 A1 PE20141649 A1 PE 20141649A1 PE 2014000448 A PE2014000448 A PE 2014000448A PE 2014000448 A PE2014000448 A PE 2014000448A PE 20141649 A1 PE20141649 A1 PE 20141649A1
- Authority
- PE
- Peru
- Prior art keywords
- rapamycin
- hydroxy
- ethyl
- pharmaceutical compositions
- prolonged
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229960002930 sirolimus Drugs 0.000 title abstract 3
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 239000010410 layer Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002035 prolonged effect Effects 0.000 abstract 2
- 239000011241 protective layer Substances 0.000 abstract 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- -1 POLOXAMERO 188 Polymers 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 239000002274 desiccant Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920000193 polymethacrylate Polymers 0.000 abstract 1
- 229920002689 polyvinyl acetate Polymers 0.000 abstract 1
- 239000011118 polyvinyl acetate Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544026P | 2011-10-06 | 2011-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141649A1 true PE20141649A1 (es) | 2014-11-14 |
Family
ID=46968222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000448A PE20141649A1 (es) | 2011-10-06 | 2012-10-03 | Composiciones farmaceuticas que comprenden 40-o-(2-hidroxi)etil-rapamicina |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20140242162A1 (OSRAM) |
| EP (1) | EP2763663B1 (OSRAM) |
| JP (1) | JP6368242B2 (OSRAM) |
| KR (1) | KR101643219B1 (OSRAM) |
| CN (1) | CN103874484B (OSRAM) |
| AR (1) | AR088232A1 (OSRAM) |
| AU (1) | AU2012320563B2 (OSRAM) |
| BR (1) | BR112014007902A2 (OSRAM) |
| CA (1) | CA2850995A1 (OSRAM) |
| CL (1) | CL2014000844A1 (OSRAM) |
| CO (1) | CO6930364A2 (OSRAM) |
| EA (1) | EA025595B1 (OSRAM) |
| ES (1) | ES2663744T3 (OSRAM) |
| GT (1) | GT201400062A (OSRAM) |
| IL (1) | IL231648A0 (OSRAM) |
| MA (1) | MA35513B1 (OSRAM) |
| MX (1) | MX2014004166A (OSRAM) |
| PE (1) | PE20141649A1 (OSRAM) |
| PH (1) | PH12014500746A1 (OSRAM) |
| SG (1) | SG11201400730VA (OSRAM) |
| TN (1) | TN2014000114A1 (OSRAM) |
| TW (1) | TWI475993B (OSRAM) |
| WO (1) | WO2013050419A1 (OSRAM) |
| ZA (1) | ZA201401961B (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201503912A (zh) * | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事(everolimus)之醫藥組合物 |
| JP6678676B2 (ja) | 2014-09-15 | 2020-04-08 | オーファザイム エー/エス | アリモクロモル製剤 |
| MX2017010872A (es) | 2015-02-27 | 2018-05-07 | Ebbu Llc | Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales. |
| CN107847491A (zh) | 2015-05-20 | 2018-03-27 | 诺华公司 | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
| JP6762158B2 (ja) * | 2015-07-28 | 2020-09-30 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| US10383860B2 (en) | 2015-07-28 | 2019-08-20 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same |
| JP6793652B2 (ja) * | 2015-09-03 | 2020-12-02 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| JP6854639B2 (ja) * | 2016-01-06 | 2021-04-07 | 日本化薬株式会社 | ラパマイシン誘導体を含有する医薬組成物及びその製造方法 |
| US12485129B2 (en) | 2016-08-29 | 2025-12-02 | Canopy Growth Corporation | Water soluble compositions comprising purified cannabinoids |
| CN110177543A (zh) | 2016-08-29 | 2019-08-27 | 凯诺比生长公司 | 包含纯化大麻素的水溶性组合物 |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| WO2018142356A1 (en) * | 2017-02-06 | 2018-08-09 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition of everolimus |
| KR102051806B1 (ko) * | 2018-01-12 | 2019-12-04 | 주식회사 종근당 | 에베로리무스를 포함하는 안정화된 약제학적 제제 |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| EP4125913A4 (en) * | 2020-03-30 | 2023-08-23 | IGIA Pharmaceuticals, Inc. | PEDIATRIC TYROSINE KINASE INHIBITOR FORMULATION |
| WO2022219652A1 (en) * | 2021-04-17 | 2022-10-20 | Bdr Pharmaceuticals International Private Limited | Novel sublingual pharmaceutical formulations for everolimus |
| KR102336007B1 (ko) * | 2021-06-23 | 2021-12-07 | 주식회사 진성이앤지 | 콘크리트용 우레탄계 방수·방식 도막재 및 이를 이용한 방수·방식 도장 공법 |
| WO2023044024A1 (en) * | 2021-09-17 | 2023-03-23 | Novelstar Pharmaceuticals Inc. | Novel ph dependent coating drug delivery system |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| AU749623B2 (en) * | 1998-03-26 | 2002-06-27 | Astellas Pharma Inc. | Sustained release preparations |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| AR045957A1 (es) * | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
| GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
| EP1902708A1 (de) * | 2006-09-25 | 2008-03-26 | Losan Pharma GmbH | Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung |
| EP2365802B1 (en) * | 2008-11-11 | 2017-08-02 | The Board of Regents,The University of Texas System | Microcapsules of rapamycin and use for treating cancer |
| CN101862297B (zh) * | 2009-04-14 | 2012-07-25 | 上海医药工业研究院 | 一种非水溶性药物的缓释微丸、其缓释口腔崩解片及其制备方法 |
-
2012
- 2012-10-03 PH PH1/2014/500746A patent/PH12014500746A1/en unknown
- 2012-10-03 EA EA201490743A patent/EA025595B1/ru not_active IP Right Cessation
- 2012-10-03 JP JP2014533869A patent/JP6368242B2/ja not_active Expired - Fee Related
- 2012-10-03 ES ES12766990.1T patent/ES2663744T3/es active Active
- 2012-10-03 CA CA2850995A patent/CA2850995A1/en not_active Abandoned
- 2012-10-03 EP EP12766990.1A patent/EP2763663B1/en active Active
- 2012-10-03 WO PCT/EP2012/069541 patent/WO2013050419A1/en not_active Ceased
- 2012-10-03 CN CN201280049427.XA patent/CN103874484B/zh not_active Expired - Fee Related
- 2012-10-03 SG SG11201400730VA patent/SG11201400730VA/en unknown
- 2012-10-03 MX MX2014004166A patent/MX2014004166A/es not_active Application Discontinuation
- 2012-10-03 PE PE2014000448A patent/PE20141649A1/es not_active Application Discontinuation
- 2012-10-03 US US14/349,166 patent/US20140242162A1/en not_active Abandoned
- 2012-10-03 KR KR1020147008751A patent/KR101643219B1/ko not_active Expired - Fee Related
- 2012-10-03 AU AU2012320563A patent/AU2012320563B2/en not_active Ceased
- 2012-10-03 BR BR112014007902A patent/BR112014007902A2/pt not_active IP Right Cessation
- 2012-10-04 AR ARP120103699A patent/AR088232A1/es unknown
- 2012-10-05 TW TW101137004A patent/TWI475993B/zh not_active IP Right Cessation
-
2014
- 2014-03-18 TN TNP2014000114A patent/TN2014000114A1/en unknown
- 2014-03-18 ZA ZA2014/01961A patent/ZA201401961B/en unknown
- 2014-03-20 IL IL231648A patent/IL231648A0/en unknown
- 2014-04-03 MA MA36880A patent/MA35513B1/fr unknown
- 2014-04-04 CO CO14073134A patent/CO6930364A2/es not_active Application Discontinuation
- 2014-04-04 GT GT201400062A patent/GT201400062A/es unknown
- 2014-04-04 CL CL2014000844A patent/CL2014000844A1/es unknown
-
2016
- 2016-11-07 US US15/345,498 patent/US20170049754A1/en not_active Abandoned
-
2018
- 2018-01-24 US US15/879,272 patent/US20180214424A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CO6930364A2 (es) | 2014-04-28 |
| JP2014528431A (ja) | 2014-10-27 |
| MX2014004166A (es) | 2015-01-15 |
| US20170049754A1 (en) | 2017-02-23 |
| EA025595B1 (ru) | 2017-01-30 |
| ZA201401961B (en) | 2015-11-25 |
| US20140242162A1 (en) | 2014-08-28 |
| KR20140058670A (ko) | 2014-05-14 |
| EA201490743A1 (ru) | 2014-07-30 |
| MA35513B1 (fr) | 2014-10-02 |
| CN103874484A (zh) | 2014-06-18 |
| EP2763663B1 (en) | 2017-12-27 |
| AU2012320563A1 (en) | 2014-04-24 |
| WO2013050419A1 (en) | 2013-04-11 |
| PH12014500746A1 (en) | 2019-07-17 |
| TN2014000114A1 (en) | 2015-07-01 |
| BR112014007902A2 (pt) | 2017-04-18 |
| EP2763663A1 (en) | 2014-08-13 |
| CN103874484B (zh) | 2016-09-21 |
| CA2850995A1 (en) | 2013-04-11 |
| AU2012320563B2 (en) | 2016-05-12 |
| IL231648A0 (en) | 2014-05-28 |
| TWI475993B (zh) | 2015-03-11 |
| KR101643219B1 (ko) | 2016-07-27 |
| GT201400062A (es) | 2015-06-02 |
| JP6368242B2 (ja) | 2018-08-01 |
| ES2663744T3 (es) | 2018-04-16 |
| CL2014000844A1 (es) | 2014-09-12 |
| TW201318625A (zh) | 2013-05-16 |
| AR088232A1 (es) | 2014-05-21 |
| US20180214424A1 (en) | 2018-08-02 |
| SG11201400730VA (en) | 2014-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141649A1 (es) | Composiciones farmaceuticas que comprenden 40-o-(2-hidroxi)etil-rapamicina | |
| PH12021550792A1 (en) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| MX373711B (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| BR112014019462A8 (pt) | Composições farmacêuticas contendo fumarato de dimetila | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| UY31171A1 (es) | Anhídridos y polímeros de esteres borónicos cíclicos y acíclicos, sus enantiómeros, sus sales farmacéuticamente aceptables, composiciones conteniéndolos y aplicaciones. | |
| BR112018012469A2 (pt) | quinolina-3-carboxamidas como inibidores da h-pgds | |
| BR112015022095A8 (pt) | composição farmacêutica, método de fabricação, composição eutética e uso de composições contendo hcl ciclobenzabrina e manitol | |
| MX2019007586A (es) | Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares. | |
| EA201591830A1 (ru) | Фармацевтические композиции, включающие эверолимус | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| CL2014003388A1 (es) | Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades. | |
| NZ630560A (en) | Pharmaceutical compositions for combination therapy | |
| CL2007003666A1 (es) | Compuestos derivados del acido nicotinico; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis, esclerosis multiple, psoriasis, entre otras. | |
| AR102869A1 (es) | Composiciones de insulina de rápida acción | |
| MX2016011810A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| BR112019024747A2 (pt) | formulações de dose fixa | |
| CL2015000615A1 (es) | Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau. | |
| AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
| PE20142457A1 (es) | Compuestos heterociclicos y sus usos | |
| DOP2017000146A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| BR112013020456A2 (pt) | nova composição antifúngica | |
| CR20160235A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| ECSP14026432A (es) | (r)-nifuratel y síntesis de (r) y (s)-nifuratel | |
| DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |